VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | HER2CLIMB: outcomes by hormone receptor status

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, provides an update on the pivotal HER2CLIMB, evaluating tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced, unresectable or HER2-positive metastatic breast cancer. In this interview, Dr Hamilton outlines the outcomes of patients treated with tucatinib by hormone receptor status. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter